A Phase I/II, Open Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia.

Trial Profile

A Phase I/II, Open Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2010

At a glance

  • Drugs Barasertib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Planned end date changed from 1 Feb 2010 to 1 Feb 2010, as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top